Marc F. Diederich

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 182 publications

Gut microbiome crosstalk in acute myeloid leukemia: mechanisms, treatment-associated dysbiosis, and translational opportunities.

Gut microbiome crosstalk in acute myeloid leukemia: mechanisms, treatment-associated dysbiosis, and translational opportunities.

Journal: Biochemical pharmacology

Published: June 10, 2026

Histone deacetylase inhibitors as venetoclax-sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives.

Histone deacetylase inhibitors as venetoclax-sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives.

Journal: British journal of pharmacology

Published: May 26, 2026

Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia.

Selective HDAC6 inhibition perturbs autophagy and enhances integrated stress response-mediated immunogenic apoptosis in chronic myeloid leukemia.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 15, 2026

Dual Beclin 1 post-translational reprogramming by BCR-ABL and HDAC6 inhibition disables autophagic flux and overcomes CML resistance.

Dual Beclin 1 post-translational reprogramming by BCR-ABL and HDAC6 inhibition disables autophagic flux and overcomes CML resistance.

Journal: Cancer letters

Published: March 19, 2026

OT-55 reshapes tolerogenic BH3-mimetic-induced apoptosis toward immunogenic cell death in acute myeloid leukemia, potentiating PD-1/Tim-3 blockade.

OT-55 reshapes tolerogenic BH3-mimetic-induced apoptosis toward immunogenic cell death in acute myeloid leukemia, potentiating PD-1/Tim-3 blockade.

Journal: Cell death & disease

Published: January 29, 2026

Marine Natural Products as Anticancer Agents 3.0.

Marine Natural Products as Anticancer Agents 3.0.

Journal: Marine drugs

Published: May 30, 2025

Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Journal: Clinical epigenetics

Published: April 25, 2025

Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients.

Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: February 12, 2025

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.

Journal: Cancer letters

Published: January 31, 2025

Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming.

Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 01, 2024

HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics.

HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics.

Journal: Haematologica

Published: August 07, 2024

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.

Journal: Biomarker research

Published: April 24, 2024

Showing 1-12 of 182

Last Updated: 09/26/2026